Inhibitors of SLC19A1 might synergize with existing therapies to counteract chemoresistance or enhance anti-tumor immunity by reducing M2 macrophage recruitment and restoring CD8+ T-cell activity. This evidence concerns the gene CD8A and neoplasm.